Used primarily in cancer immunotherapy research, this compound acts as an inhibitor of the indoleamine 2,3-dioxygenase (IDO) enzyme. By blocking IDO, it helps prevent the suppression of T-cell activity, thereby enhancing the immune system's ability to target and destroy tumor cells. It has been investigated in preclinical and clinical studies as an adjuvant in combination with other immunotherapies, such as checkpoint inhibitors, to improve anti-tumor responses. Its role in modulating immune tolerance in the tumor microenvironment makes it a significant focus in oncology drug development.